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Abstract
Given that liver failure continues to pose an enormous clinical
challenge, the concept of hepatic dialysis has enjoyed significant
interest. In particular, many investigations have examined the
therapeutic mechanisms and efficacy of artificial albumin dialysis
based systems in acute on chronic liver failure, the results of which
have been conflicting. Albumin dialysis systems do not appear to
significantly decrease serum concentrations of inflammatory
cytokines in severe acute on chronic liver failure. Thus, if these
treatments do result in clinical improvement, then other therapeutic
mechanisms must be involved.
In a previous issue of Critical Care, Stadlbauer and colleagues
[1] examined the effects of two artificial albumin dialysis
systems on the removal of cytokines in the setting of acute on
chronic liver failure. In the absence of liver transplantation,
patients with liver failure face limited therapeutic interventions
and ultimately suffer multiple organ system dysfunction. The
shortage of donor livers and the growing number of patients
with advanced liver disease has stimulated active interest in
extracorporeal liver support devices, including artificial and
bio-artificial systems. Although artificial support systems have
focused primarily on albumin dialysis techniques to achieve
detoxification, bio-artificial systems potentially have the added
advantage of simulating the liver’s synthetic functions.
Although no large multicentered trials have yet established
the role of liver assist devices, a large systematic review [2]
suggests that artificial liver support systems reduce mortality
in acute on chronic liver failure compared with standard
medical therapy. This finding has led investigators to focus
their attention on the potential mechanisms of therapeutic
benefits of artificial assist devices in acute on chronic liver
failure, including removal of proinflammatory cytokines [3].
This area of investigation has been addressed in other small
studies, with conflicting results. For example, one recent
study [4] suggested a decrease in serum cytokine levels
following treatment, with an associated improvement in
patient prognosis, whereas a second recent study [5] found
no effect of treatment on cytokines. A crucial factor
influencing the outcome of these studies is the severity of
liver disease, as measured objectively using the Mayo End
Stage Liver Disease score, which may correlate with the
‘cytokine burden’. In the study by Stadlbauer and colleagues
included in a previous issue [1], the patient population is
characterized by a high degree of disease severity, as
evidenced by a mean Mayo End Stage Liver Disease score of
31. Unfortunately, the study demonstrates no efficacy of
artificial liver support systems in decreasing cytokine levels,
and the authors conclude that a high rate of cytokine
production that exceeds the rate of detoxification probably
accounts for their findings.
Indeed, the results of the study by Stadlbauer and colleagues
[1] are reminiscent of early studies of hemofiltration for
treatment of sepsis [6], several of which revealed that
cytokine clearance was possible but removal rates were
insufficient to permit meaningful changes in plasma
concentrations [7]. Results from clinical studies similarly did
not support a role for low volume, ‘renal dose’ hemofiltration
for treatment of sepsis [8]. The reasons for the relatively poor
clearance of interleukin-6 with the MARS™ (Gambro AB,
Stockholm, Sweden) and Prometheus™ (Fresenius Medical
Care AG & Co. KGaA, Homburg, Germany) systems are
uncertain. Much greater clearance has been reported with
large-pore hemofiltration in animals and with associated
physiologic improvement [9]. However, clearances for
interleukin-10 (Prometheus™) and tumor necrosis factor
(TNF; both systems) were significantly better. The reason why
these clearances did not translate into changes in plasma
concentrations was probably not related to high production
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rates, as suggested by the authors, because circulating levels
were low (TNF levels were near normal) and endogenous
clearance was almost certainly impaired. Instead, the lack of
efficacy could be related to the short treatment time, the
removal of circulating inhibitors (such as soluble TNF
receptors), or even enhanced production of mediators in
response to treatment.
Nevertheless, despite its small sample size, the study by
Stadlbauer and colleagues [1] suggests that if liver assist
therapy is effective, then mechanisms other than cytokine
removal must be important. The field of bio-artificial liver
support has been an area of active investigation [10], and the
prospect of an extracorporeal device that will reproduce both
the synthetic and detoxification functions of the liver will
sustain continued research in this field.
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